Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2026-05-25 Earnings Release
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science annonce que le titre AB Science continue d’être couvert par Maxim Group, avec un objectif de cours de 4,00 € par action
Earnings Release Classification · 78% confidence The document is a press release by AB Science announcing the publication of its full-year 2025 results and related corporate updates (clinical trial insurance subscription), along with an analyst recommendation and price target. It does not attach the full report but serves as the initial public release of the financial results highlights. This matches the definition of an Earnings Release (ER). FY 2025
2026-05-25 French
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
Regulatory Filings Classification · 75% confidence The document is a company press release announcing that an investment bank (Maxim Group) has reiterated its Buy recommendation on the company’s stock and discusses a clinical trial insurance policy and financing implications. It does not present financial statements (10-K/IR), earnings highlights (ER), dividend info (DIV), management/board changes (MANG), capital raises or M&A filings, or any detailed investor presentation slides. It is a general PR announcement filed publicly, falling into the miscellaneous regulatory announcement category. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-25 English
AB Science reports its revenues for the year 2025 and provides an update on its activities
Earnings Release Classification · 90% confidence The document is a press release announcing the company's annual financial results (operating loss, cash position) as of December 31, 2025, along with key corporate and clinical development updates. It provides only high-level financial highlights rather than full financial statements or detailed analysis. This matches the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-05-13 English
AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2025 et présente un point sur ses activités
Earnings Release Classification · 85% confidence The document is a press release titled “AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS ANNUELS AU 31 DÉCEMBRE 2025…” providing high-level financial metrics (operating deficit, cash position) and key corporate and clinical development highlights. It summarizes the annual results in bullet points rather than containing full financial statements or detailed disclosures. This format corresponds to an Earnings Release (initial announcement of periodical financial results with key highlights only), not a full Annual Report or an official regulatory filing. FY 2025
2026-05-13 French
Rapport annuel financier 2025
Annual Report Classification · 100% confidence The document is titled 'Rapport Financier Annuel 2025' which translates to 'Annual Financial Report 2025'. It contains detailed sections including company presentation, risk factors, governance, remuneration, capital structure, shareholder information, financial results, consolidated and social accounts, auditor reports, and other detailed financial and corporate information. The length is substantial (15,000 characters) and it includes actual financial statements and auditor reports, not just announcements or summaries. The presence of detailed financial data, management commentary, auditor reports, and comprehensive corporate information aligns with the definition of an Annual Report (10-K). Therefore, this document is classified as an Annual Report (10-K). FY 2025
2026-05-13 English
AB Science annonce le succès d’un placement prive de 3,2 millions d’euros
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the successful completion of a private placement (augmentation de capital) raising €3.2 million, describes the terms of the share issuance, the new share count, admission to trading, use of proceeds, and lock-up arrangements. It is not a full financial report but a financing activity update focused on capital structure and fundraising. This clearly falls under a Capital/Financing Update.
2026-04-29 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.